New RSV therapies may accelerate the emergence of resistant strains
Pharmaceutical Technology
FEBRUARY 1, 2023
Pharmaceutical companies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Despite strong efforts and scientific advances, a safe and effective vaccine for RSV has yet to be approved for any patient population.
Let's personalize your content